Ocular effects of pegylated interferon-alpha in patients with chronic hepatitis B

Basit Öğe Kaydı
dc.contributor.authorKoktekir, Bengu Ekinci
dc.contributor.authorSumer, Sua
dc.contributor.authorBakbak, Berker
dc.contributor.authorGedik, Sansal
dc.contributor.authorGonul, Saban
dc.contributor.authorUral, Onur
dc.date.accessioned2020-03-26T18:42:41Z
dc.date.available2020-03-26T18:42:41Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPurpose: To evaluate the early retinal changes and its reflection on the visual field examination in chronic hepatitis B (CHB) patients using pegylated interferon-alpha (PEGIFN-alpha) monotherapy. Patients and methods: Thirty eyes of fifteen patients with CHB were examined prospectively for changes in the fundus examination and visual field examination (both Humphrey Perimetry and Frequency Doubling Perimetry). The patients were examined before and in 3 months intervals after starting the PEGIFN-alpha treatment. The changes in the fundus examination were noted and the visual field examinations, retinal nerve fiber thickness, Schirmer scores and color vision before and at 3 months of the treatment were compared. The statistical evaluation was performed with paired-t test, using SPSS 16.0 Inc. (Chicago, IL). Results: The mean age of the 15 patients (seven male, eight female) was 52.5 +/- 12.4 years. There was no significant retinal change in none of the patients. Neither the visual field examination with Humphrey Field Analyzer nor the Frequency Doubling Perimetry results has demonstrated any significant change during 3 months follow-up. There was a statistically significant increase in the retinal nerve fiber layer (RNFL) thickness; while Schirmer test scores for dry eye assessment was significantly decreased. Conclusion: PEGIFN-alpha monotherapy, which is used for treatment of CHB, may cause some changes in the thickness of RNFL that may necessitate the close follow-up for further morphological changes of the optic disc in these patients.en_US
dc.identifier.doi10.3109/15569527.2013.775656en_US
dc.identifier.endpage278en_US
dc.identifier.issn1556-9527en_US
dc.identifier.issue4en_US
dc.identifier.pmid23477604en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage275en_US
dc.identifier.urihttps://dx.doi.org/10.3109/15569527.2013.775656
dc.identifier.urihttps://hdl.handle.net/20.500.12395/29686
dc.identifier.volume32en_US
dc.identifier.wosWOS:000323527300003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherINFORMA HEALTHCAREen_US
dc.relation.ispartofCUTANEOUS AND OCULAR TOXICOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectChronic hepatitis Ben_US
dc.subjectpegylated interferon-alphaen_US
dc.subjectretinal nerve fiber layeren_US
dc.subjectvisual fielden_US
dc.titleOcular effects of pegylated interferon-alpha in patients with chronic hepatitis Ben_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu